Sanofi Developing Booster Shot... "Antibodies Increased 9 to 43 Times"

Clinical Trial of Cross-Vaccination with Pfizer, Moderna, AstraZeneca, and Janssen Vaccines
Aiming for Launch Next Year

[Image source=Yonhap News]

[Asia Economy Reporter Ki Ha-young]French pharmaceutical company Sanofi announced that its COVID-19 booster shot under development induced a strong immune response across all age groups, regardless of the type of vaccine previously received.

On the 15th (local time), Sanofi released a press statement announcing the initial results of the Phase 3 clinical trial of the booster shot being developed in collaboration with the UK-based GlaxoSmithKline (GSK).

Sanofi and GSK explained that antibody levels increased 9 to 43 times after administering the booster shot candidate to individuals who had completed vaccination with Pfizer-BioNTech, Moderna, AstraZeneca, or Janssen vaccines.

However, they did not disclose specific figures such as which of the existing vaccines approved by the European Union (EU) showed the highest preventive effect when used in a heterologous booster regimen.

They noted that the rapidly spreading Omicron variant was not reflected in the clinical trial, as the trial began recruiting participants in the third quarter of 2021 when COVID-19 cases started rising again due to the spread of the Delta variant.

Sanofi and GSK are also conducting clinical trials on individuals who have not contracted COVID-19 and plan to announce comprehensive results in the first quarter of next year.

Sanofi, which lagged behind in the COVID-19 vaccine development race, initially aimed to obtain vaccine approval within this year. However, due to delays in the clinical trial schedule, the target launch date has been postponed to next year.

This content was produced with the assistance of AI translation services.